Journal of the American Heart Association, ISSN 2047-9980, 10/2016, Volume 5, Issue 10, p. n/a
Background The extent to which angina is associated with future cardiovascular events in patients with coronary artery disease has long been debated. Methods...
cardiovascular events | coronary artery disease | angina | Cardiovascular events | Coronary artery disease | Angina | CARDIAC & CARDIOVASCULAR SYSTEMS | OUTPATIENTS | MYOCARDIAL-ISCHEMIA | RISK | SYMPTOMS | RATES | HEART-DISEASE | SOUL | PECTORIS | CLARIFY REGISTRY | CLINICAL-OUTCOMES | United States - epidemiology | Myocardial Infarction - epidemiology | Prognosis | Humans | Middle Aged | Proportional Hazards Models | Hospitalization - statistics & numerical data | Male | Case-Control Studies | Myocardial Revascularization - utilization | Angina, Stable - epidemiology | Cardiovascular Diseases - mortality | Female | Registries | Stroke - epidemiology | Aged | Coronary Artery Disease - epidemiology | Odds Ratio | Heart Failure - epidemiology
cardiovascular events | coronary artery disease | angina | Cardiovascular events | Coronary artery disease | Angina | CARDIAC & CARDIOVASCULAR SYSTEMS | OUTPATIENTS | MYOCARDIAL-ISCHEMIA | RISK | SYMPTOMS | RATES | HEART-DISEASE | SOUL | PECTORIS | CLARIFY REGISTRY | CLINICAL-OUTCOMES | United States - epidemiology | Myocardial Infarction - epidemiology | Prognosis | Humans | Middle Aged | Proportional Hazards Models | Hospitalization - statistics & numerical data | Male | Case-Control Studies | Myocardial Revascularization - utilization | Angina, Stable - epidemiology | Cardiovascular Diseases - mortality | Female | Registries | Stroke - epidemiology | Aged | Coronary Artery Disease - epidemiology | Odds Ratio | Heart Failure - epidemiology
Journal Article
The Lancet, ISSN 0140-6736, 07/2019, Volume 394, Issue 10193, pp. 121 - 130
Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk...
MEDICINE, GENERAL & INTERNAL | BASE-LINE | EVENTS | EFFICACY | SAFETY | PEPTIDE-1 RECEPTOR AGONISTS | Myocardial infarction | Heart attacks | Peptides | Control methods | Glucagon | Clinical trials | Cardiovascular disease | Population studies | Cancer therapies | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Drug dosages | Glucagon-like peptide 1 | Women | Cerebral infarction | Enzymes | Stroke | Middle age | Diabetes mellitus | Health risks | Hypoglycemia | Risk analysis | Angina pectoris | Disease control | Cholesterol | Thyroid cancer | Agonists | Diabetes | Cardiovascular diseases | Health risk assessment | Elderly
MEDICINE, GENERAL & INTERNAL | BASE-LINE | EVENTS | EFFICACY | SAFETY | PEPTIDE-1 RECEPTOR AGONISTS | Myocardial infarction | Heart attacks | Peptides | Control methods | Glucagon | Clinical trials | Cardiovascular disease | Population studies | Cancer therapies | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Drug dosages | Glucagon-like peptide 1 | Women | Cerebral infarction | Enzymes | Stroke | Middle age | Diabetes mellitus | Health risks | Hypoglycemia | Risk analysis | Angina pectoris | Disease control | Cholesterol | Thyroid cancer | Agonists | Diabetes | Cardiovascular diseases | Health risk assessment | Elderly
Journal Article
2016, ISBN 0739197908, xxiii, 177
Book
The Lancet, ISSN 0140-6736, 07/2019, Volume 394, Issue 10193, pp. 131 - 138
Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the...
MEDICINE, GENERAL & INTERNAL | BASE-LINE | LIRAGLUTIDE | INCRETIN | CARDIOVASCULAR OUTCOMES | DISEASE | Myocardial infarction | Therapy | Peptides | Glucagon | Cardiovascular disease | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Urine | Creatinine | Cerebral infarction | Stroke | Kidneys | Epidermal growth factor receptors | Diabetes mellitus | Health risks | Risk analysis | Disease control | Agonists | Microvasculature | Diabetes | Kidney diseases | Renal replacement therapy | Gastrointestinal surgery | Cardiovascular diseases | Health risk assessment
MEDICINE, GENERAL & INTERNAL | BASE-LINE | LIRAGLUTIDE | INCRETIN | CARDIOVASCULAR OUTCOMES | DISEASE | Myocardial infarction | Therapy | Peptides | Glucagon | Cardiovascular disease | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Urine | Creatinine | Cerebral infarction | Stroke | Kidneys | Epidermal growth factor receptors | Diabetes mellitus | Health risks | Risk analysis | Disease control | Agonists | Microvasculature | Diabetes | Kidney diseases | Renal replacement therapy | Gastrointestinal surgery | Cardiovascular diseases | Health risk assessment
Journal Article